Just out in @BloodJournal – our study exploring the origin of late relapses in T-ALL. Here's a short thread with our unexpected results!
https://t.co/bWACBlepRb
Focal deletions of noncoding regions in cancer genomes can have unexpected consequences. Out now in @BloodJournal, we’ve discovered an intriguing mechanism of oncogene activation whereby focal deletion of a ‘promoter tether’ leads to aberrant expression of IRX3 in T-ALL. Thread👇
Liza is a dedicated paediatrician who lost her husband (another well respected and loved neonatologist) to COVID. Please read and consider signing and sharing this:
https://t.co/p9Fr9b5UcV
Time to bid a fond farewell to @uclcancer having completed my @CRUKresearch Clinician Scientist Fellowship. It’s been an incredible 6 years working on some great projects that I hope have progressed our knowledge of childhood leukaemia
Huge thanks to my supervisor @Marcrmansour for endless patience and support, and the many members of the lab. Particular shout-outs to the amazing scientists willing to help an incompetent medic and who made it all so enjoyable! @minimolecule@VLlombs Joana Costa @there_leon
'Whole genome sequencing is special because we can look at the entire genome instead of parts of a genome.'
Genome expert @AngusHodder says 'if we know a child has a less risky form of cancer, we can give them less intensive treatment'
#SJUK https://t.co/immDwEwbK2
📺 Sky 501
Thank you to all the patients and families involved in this pivotal study which proves the real time, real world evidence for the benefit of whole genome sequence in childhood cancer.
Massive cuts in clinician scientist fellowships over the last few years and an overlong application process that engenders attrition suggests this is less of a CRUK priority than this article would have you believe
Following the success of @CRUKresearch’s Clinical Academic Training Programme over the past 5 years, this is an important further investment in the next generation of clinician scientists across Scotland and England. Clinician scientists play an essential role in bridging the gap between discovery research and clinical research involving patients, and this funding will help accelerate the development of cancer treatments in the future.
https://t.co/hyQHnXcUSI
@generoom @BloodJournal Good questions Mike. First thing is to get these well-validated nc mutations reported on the WGS! We need a bigger dataset to ascertain rate - should be available from US soon…
Just out in @BloodJournal – our study exploring the origin of late relapses in T-ALL. Here's a short thread with our unexpected results!
https://t.co/bWACBlepRb
To complete the story we were lucky to be able to go back to the stored neonatal blood spot sample for one patient, showing the same LMO2 non-coding lesion was present at birth confirming that it had occurred in utero – the first time this has been shown for a non-coding lesion